How Hemlibra dosing works
Emicizumab (Hemlibra) is a bispecific antibody that bridges activated factor IX and factor X, reproducing the cofactor job that missing factor VIII should do in the clotting cascade. It is given subcutaneously as routine prophylaxis to prevent or reduce bleeding in hemophilia A, in adults and children from newborn age upwards, with or without factor VIII inhibitors. The dosing structure has two phases, and both are pure mg/kg arithmetic on actual body weight. The loading dose is 3 mg/kg once weekly for the first 4 weeks, the same for everyone, to build blood levels up quickly. From week 5, one of three maintenance regimens is used, and all three deliver the same average weekly amount: 1.5 mg/kg once weekly, 3 mg/kg every 2 weeks, or 6 mg/kg every 4 weeks. The label leaves the choice to healthcare provider preference, explicitly mentioning regimens that may increase patient adherence: the 4-weekly option means 13 injections a year, the weekly option 52 smaller ones. This calculator returns the dose for the chosen regimen and, for comparison, all four regimens at the entered weight.
Worked example: the 70 kg adult
At 70 kg the numbers are: loading 210 mg once a week for 4 weeks; maintenance 105 mg weekly, 210 mg every 2 weeks, or 420 mg every 4 weeks. Notice that the loading dose and the 2-weekly maintenance dose are the same milligram figure at any weight, since both are 3 mg/kg; what changes is how often it is repeated and for how long. The same table at other weights shows how the arithmetic scales:
| Weight | Loading 3 mg/kg (weekly x 4) | Maintenance 1.5 mg/kg weekly | Maintenance 3 mg/kg q2w | Maintenance 6 mg/kg q4w |
|---|---|---|---|---|
| 10 kg | 30 mg | 15 mg | 30 mg | 60 mg |
| 30 kg | 90 mg | 45 mg | 90 mg | 180 mg |
| 50 kg | 150 mg | 75 mg | 150 mg | 300 mg |
| 70 kg | 210 mg | 105 mg | 210 mg | 420 mg |
| 100 kg | 300 mg | 150 mg | 300 mg | 600 mg |
From milligrams to millilitres: the two concentrations
The dose in milligrams is only half the task; the injection is drawn up by volume, and Hemlibra is supplied in two concentrations that must never be mixed up or combined in one syringe. The 30 mg/mL presentation comes as 12 mg in 0.4 mL and 30 mg in 1 mL single-dose vials. The 150 mg/mL presentation comes as 60 mg in 0.4 mL, 105 mg in 0.7 mL, 150 mg in 1 mL and 300 mg in 2 mL. Volume is simply dose divided by concentration: the 210 mg dose for a 70 kg patient is 1.4 mL from a 150 mg/mL vial but 7 mL from 30 mg/mL vials, which is why larger doses are almost always drawn from the concentrated presentation and the dilute vials exist for small paediatric doses, where they allow fine volumes (a newborn's 10.5 mg loading dose is 0.35 mL at 30 mg/mL). Two hard rules from the administration instructions: vials of different concentrations must not be combined in a single injection when making up a dose, and a volume greater than 2 mL per injection should not be administered, so a larger total is divided into separate injections at different sites. The calculator applies both rules and tells you the injection count whenever the volume crosses 2 mL.
Starting, switching and missed doses
The label's transition rules are specific. Prophylactic use of bypassing agents is discontinued the day before starting Hemlibra, while factor VIII prophylaxis may be continued during the first week. This matters because of the boxed warning: cases of thrombotic microangiopathy and thromboembolism were reported when patients on Hemlibra received activated prothrombin complex concentrate (aPCC) at an average cumulative amount above 100 units/kg over 24 hours for 24 hours or more; if aPCC cannot be avoided, the label directs monitoring for these events and stopping both drugs if symptoms occur. For a missed dose, the instruction is to administer it as soon as possible and then resume the usual schedule, and never to give two doses on the same day to catch up. Hemlibra is intended for use under healthcare provider guidance; after training, a patient or caregiver may self-inject, but self-administration is not recommended for children under 7 years of age. One further laboratory caveat from the label: emicizumab interferes with aPTT-based clotting tests and aPTT-based factor VIII activity assays, so those standard tests cannot be used to monitor its effect.
References
HEMLIBRA (emicizumab-kxwh) injection, for subcutaneous use. FDA-approved prescribing information, Genentech, Inc. (DailyMed, setid 2483adba-fab6-4d1b-96c5-c195577ed071): section 1 indications (routine prophylaxis in hemophilia A, newborn and older, with or without inhibitors); 2.1 recommended dosage (loading 3 mg/kg once weekly for 4 weeks; maintenance 1.5 mg/kg weekly, 3 mg/kg every 2 weeks or 6 mg/kg every 4 weeks; discontinuation of bypassing agents the day before starting; missed dose instructions); 2.2 preparation and administration; section 3 dosage forms and strengths (12 mg/0.4 mL, 30 mg/1 mL, 60 mg/0.4 mL, 105 mg/0.7 mL, 150 mg/1 mL, 300 mg/2 mL); boxed warning on thrombotic microangiopathy and thromboembolism with aPCC.